Is SOLV a good stock to buy? We came across a bullish thesis on Solventum Corporation on r/ValueInvesting by raytoei. In this article, we will summarize the bulls’ thesis on SOLV. Solventum Corporation’s share was trading at $82.46 as of June 9th. SOLV’s trailing and forward P/E were 10.09 and 12.58 respectively according to Yahoo Finance.
al7/Shutterstock.com
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. SOLV remains a financially complex but increasingly investable turnaround under CEO Bryan Hanson, who was recruited specifically to execute the separation and restore operational discipline after previously leading a successful restructuring at Zimmer Biomet.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company has been actively streamlined, most notably through the sale of its filtration business to Thermo Fisher, which has helped reduce leverage and sharpen strategic focus on its core healthcare franchises, although reported results still reflect significant separation and restructuring noise that obscures underlying earnings power. For FY2026, management guides organic revenue growth of +2.0% to +3.0%, or +3.0% to +4.0% excluding SKU exits, alongside adjusted EPS of $6.40 to $6.60 and free cash flow of approximately $200 million, equating to roughly $1.15 per share.
However, when adjusting for near-term dis-synergies, including estimated separation costs of 0.73 per quarter and restructuring costs of 0.18 per quarter, normalized free cash flow potential could approach $4.79 per share once transitional burdens fade. This gap highlights how depressed current cash generation appears relative to steady-state earnings power. Management’s medium-term framework further strengthens the investment case, targeting 4% to 5% organic growth, roughly 10% EPS CAGR, operating margins expanding to 23% to 25% by 2028, and free cash flow conversion reaching 80%, signaling a clear path toward higher-quality earnings.
Under a conservative valuation framework using a 9% discount rate, 5% growth over five years, and a 3% terminal growth rate, intrinsic value is estimated at approximately $82 per share at the start of 2026. With the stock trading near $73, the market appears to underappreciate normalization of cash flows and margin expansion, creating an attractive risk-reward profile as execution under Hanson gradually de-risks the turnaround and unlocks underlying value.
Previously, we covered a bullish thesis on ResMed Inc. (RMD) by LongTermValue Research in April 2025, which highlighted strong sleep apnea demand, SaaS-driven monitoring, and market share gains. RMD’s stock price has depreciated by 11.68% since our coverage. raytoei shares a similar view but emphasizes Solventum’s turnaround-led undervaluation and margin recovery versus ResMed’s quality-compounding profile in the healthcare equipment space.
Solventum Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held SOLV at the end of the first quarter which was 42 in the previous quarter. While we acknowledge the risk and potential of SOLV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SOLV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
